Immunovant, Inc. (IMVT) shareholders
Close on Nov 17, 2026Market cap $6.86BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roivant Sciences Ltd. | 113,327,007 | 55.90% | 13D (active) amendment | Dec 12, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (10.10%) | 17,078,093 | 10.10% | 13G (passive) amendment | Feb 28, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (8.40%) | 14,729,555 | 8.40% | 13G (passive) amendment | Sep 30, 2025 |
| Deep Track Biotechnology Master Fund, Ltd. Joint filing with Deep Track Capital, LP (5.59%), David Kroin (5.59%) | 9,500,000 | 5.59% | 13G (passive) | Mar 19, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMVT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 16,186,469 | 7.84% | $623.66M | −761,419 | 0.03% |
| Deep Track Capital, LP | 9,341,151 | 4.52% | $359.91M | −2,185,820 | 5.24% |
| BlackRock, Inc. | 7,180,897 | 3.48% | $276.68M | +606,400 | 0.00% |
| Farallon Capital Management LLC | 5,805,000 | 2.81% | $223.67M | +4,259,000 | 1.03% |
| Baker Bros. Advisors LP | 5,435,220 | 2.63% | $209.42M | −22,661 | 1.05% |
| State Street Corp | 4,617,005 | 2.24% | $177.89M | +79,076 | 0.01% |
| Morgan Stanley | 4,534,833 | 2.20% | $174.73M | +657,956 | 0.01% |
| TCG Crossover Management, LLC | 4,457,988 | 2.16% | $171.77M | – | 4.13% |
| Vanguard Portfolio Management LLC | 3,910,509 | 1.89% | $150.67M | +205,604 | 0.01% |
| Vanguard Capital Management LLC | 3,638,681 | 1.76% | $140.20M | +18,631 | 0.00% |
| Jennison Associates LLC | 3,310,238 | 1.60% | $127.54M | +113,533 | 0.08% |
| Rtw Investments, LP | 3,177,849 | 1.54% | $122.44M | – | 1.05% |
| Two Seas Capital LP | 3,148,505 | 1.52% | $121.31M | −53,457 | 2.40% |
| ADAR1 Capital Management, LLC | 2,330,716 | 1.13% | $89.80M | −348,294 | 4.11% |
| Geode Capital Management, LLC | 2,234,602 | 1.08% | $86.12M | +142,500 | 0.00% |
| T. Rowe Price Investment Management, Inc. | 2,222,101 | 1.08% | $85.62M | −1,390,759 | 0.06% |
| Woodline Partners LP | 1,975,869 | 0.96% | $76.13M | – | 0.24% |
| Price T Rowe Associates Inc /Md/ | 1,829,210 | 0.89% | $70.48M | +1,489,603 | 0.01% |
| Goldman Sachs Group Inc | 1,751,183 | 0.85% | $67.47M | −33,924 | 0.01% |
| Armistice Capital, LLC | 1,736,000 | 0.84% | $66.89M | −1,828,916 | 0.82% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 226 | 110M | 53.5% | 39 / 74 | 79 / 24 | 13M | 14M |
| Q1 2026 | 215 | 111M | 53.9% | 46 / 93 | 40 / 25 | 22M | 12M |
| Q4 2025 | 197 | 109M | 52.9% | 40 / 75 | 54 / 26 | 23M | 9M |
| Q3 2025 | 186 | 95M | 46.1% | 35 / 64 | 51 / 16 | 9M | 10M |
| Q2 2025 | 168 | 96M | 46.6% | 24 / 74 | 47 / 48 | 11M | 10M |
| Q1 2025 | 193 | 95M | 45.9% | 36 / 91 | 43 / 27 | 22M | 9M |
| Q4 2024 | 186 | 82M | 39.8% | 38 / 68 | 61 / 29 | 14M | 11M |
| Q3 2024 | 182 | 80M | 38.6% | 21 / 71 | 66 / 35 | 17M | 8M |
| Q2 2024 | 197 | 76M | 36.6% | 25 / 81 | 66 / 35 | 15M | 15M |
| Q1 2024 | 209 | 75M | 36.3% | 28 / 82 | 79 / 46 | 15M | 11M |
| Q4 2023 | 228 | 72M | 34.6% | 72 / 68 | 72 / 24 | 17M | 13M |
| Q3 2023 | 181 | 68M | 33.0% | 61 / 64 | 44 / 24 | 23M | 11M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
204 funds held IMVT in Q2 2026, 45% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IMVT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 5,098,631 | 2.47% | $169.78M | 0.17% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,600,086 | 1.26% | $100.18M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,576,556 | 1.25% | $99.27M | 0.92% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,190,157 | 1.06% | $84.39M | 0.10% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,881,798 | 0.91% | $72.51M | 0.04% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 1,402,578 | 0.68% | $46.71M | 0.17% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 1,113,759 | 0.54% | $37.09M | 0.15% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,086,290 | 0.53% | $41.85M | 0.09% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 991,466 | 0.48% | $38.20M | 0.41% | Jun 30, 2026 |
| PGIM Jennison Small Company Fund | 981,541 | 0.48% | $37.82M | 1.09% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 932,980 | 0.45% | $36.03M | 0.11% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 887,905 | 0.43% | $34.21M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 787,645 | 0.38% | $30.35M | 0.20% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 642,000 | 0.31% | $24.74M | 0.25% | Jun 30, 2026 |
| iShares Biotechnology ETF | 573,747 | 0.28% | $22.11M | 0.24% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Eric Venker | Chief Executive Officer, Director | 257,075 | 0.12% | Oct 5, 2026 |
| Peter Salzmann | Chief Executive Officer, Director | 1,178,191 | 0.57% | Apr 17, 2025 |
| Tiago Girao | Chief Financial Officer | 234,192 | 0.11% | Oct 30, 2026 |
| Jay S. Stout | Chief Technology Officer | 198,937 | 0.10% | Oct 23, 2026 |
| Tuyl Christopher Van | Chief Legal Officer | 175,218 | 0.08% | Oct 9, 2026 |
| Melanie Gloria | Chief Operating Officer | 217,060 | 0.11% | Oct 9, 2026 |
| Michael Geffner | Chief Medical Officer | 217,958 | 0.11% | Oct 24, 2025 |
| Eva Renee Barnett | Chief Financial Officer | 396,774 | 0.19% | Apr 17, 2025 |
| William L. Macias | Chief Medical Officer | 357,353 | 0.17% | Feb 21, 2025 |
| Mark S. Levine | Chief Legal Officer | 319,228 | 0.15% | Nov 22, 2024 |
| Atul Pande | Director | 136,731 | 0.07% | Nov 12, 2026 |
| Andrew J. Fromkin | Director | 131,400 | 0.06% | May 29, 2026 |
| Robert Graham Susman | Director | 36,394 | 0.02% | May 1, 2026 |
| Douglas J. Hughes | Director | 134,653 | 0.07% | Apr 9, 2026 |
| Jake Bauer | Director | 38,896 | 0.02% | Apr 9, 2026 |
| Frank Torti | Director | 1,009,228 | 0.49% | Apr 9, 2026 |
| Sciences Ltd. Roivant | Director, 10% owner | 113,317,007 | 54.86% | Dec 12, 2025 |
| George V. Migausky | Director | 157,251 | 0.08% | Apr 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Atul Pande Director | Nov 11, 2026 | Sale(10b5-1 plan) | −3,000 | $36.00 | $108.00K | 116,731 |
| Atul Pande Director | Nov 11, 2026 | Option exercise | +3,000 | $8.43 | $25.29K | 119,731 |
| Tiago Girao Chief Financial Officer | Oct 28, 2026 | Sale | −6,606 | $28.50 | $188.27K | 234,192 |
| Jay S. Stout Chief Technology Officer | Oct 21, 2026 | Sale | −2,595 | $28.94 | $75.10K | 198,937 |
| Tuyl Christopher Van Chief Legal Officer | Oct 7, 2026 | Sale | −1,327 | $32.06 | $42.54K | 175,218 |
| Melanie Gloria Chief Operating Officer | Oct 7, 2026 | Sale | −2,241 | $32.06 | $71.85K | 217,060 |
| Jay S. Stout Chief Technology Officer | Oct 7, 2026 | Sale | −1,596 | $32.06 | $51.17K | 201,532 |
| Jay S. Stout Chief Technology Officer | Oct 7, 2026 | Sale | −2,213 | $32.06 | $70.95K | 203,128 |
| Eric Venker Chief Executive Officer, Director | Oct 2, 2026 | Sale | −3,506 | $34.11 | $119.59K | 257,075 |
| Eric Venker Chief Executive Officer, Director | Oct 1, 2026 | Returned to company | −85,886 | $33.65 | $2.89M | 260,581 |
| Eric Venker Chief Executive Officer, Director | Oct 1, 2026 | Option exercise | +92,187 | $14.46 | $1.33M | 346,467 |
| Tuyl Christopher Van Chief Legal Officer | Sep 23, 2026 | Sale | −2,846 | $36.36 | $103.48K | 176,545 |
| Atul Pande Director | Aug 28, 2026 | Option exercise | +1,500 | $8.43 | $12.65K | 118,231 |
| Atul Pande Director | Aug 28, 2026 | Sale(10b5-1 plan) | −1,500 | $43.27 | $64.91K | 116,731 |
| Melanie Gloria Chief Operating Officer | Aug 20, 2026 | Sale | −3,056 | $44.16 | $134.95K | 219,301 |
| Atul Pande Director | Jul 24, 2026 | Sale(10b5-1 plan) | −1,500 | $39.80 | $59.70K | 116,731 |
| Atul Pande Director | Jul 24, 2026 | Option exercise | +1,500 | $8.43 | $12.65K | 118,231 |
| Tiago Girao Chief Financial Officer | Jul 23, 2026 | Sale | −6,798 | $38.69 | $263.01K | 240,798 |
| Jay S. Stout Chief Technology Officer | Jul 23, 2026 | Sale | −2,857 | $38.69 | $110.54K | 205,341 |
| Jay S. Stout Chief Technology Officer | Jul 8, 2026 | Sale | −1,906 | $39.53 | $75.34K | 209,779 |
| Jay S. Stout Chief Technology Officer | Jul 8, 2026 | Sale | −105 | $39.99 | $4.20K | 209,674 |
| Jay S. Stout Chief Technology Officer | Jul 8, 2026 | Sale | −77 | $39.99 | $3.08K | 208,198 |
| Jay S. Stout Chief Technology Officer | Jul 8, 2026 | Sale | −1,399 | $39.53 | $55.30K | 208,275 |
| Tuyl Christopher Van Chief Legal Officer | Jul 8, 2026 | Sale | −1,143 | $39.53 | $45.18K | 179,454 |
| Tuyl Christopher Van Chief Legal Officer | Jul 8, 2026 | Sale | −63 | $39.99 | $2.52K | 179,391 |
| Melanie Gloria Chief Operating Officer | Jul 8, 2026 | Sale | −1,930 | $39.53 | $76.29K | 222,463 |
| Melanie Gloria Chief Operating Officer | Jul 8, 2026 | Sale | −106 | $39.99 | $4.24K | 222,357 |
| Eric Venker Chief Executive Officer, Director | Jul 2, 2026 | Sale | −3,092 | $38.48 | $118.98K | 254,280 |
| Eric Venker Chief Executive Officer, Director | Jul 1, 2026 | Option exercise | +92,188 | $14.46 | $1.33M | 344,001 |
| Eric Venker Chief Executive Officer, Director | Jul 1, 2026 | Returned to company | −86,629 | $38.14 | $3.30M | 257,372 |
| Melanie Gloria Chief Operating Officer | Jun 26, 2026 | Sale | −2,966 | $38.95 | $115.53K | 224,393 |
| Melanie Gloria Chief Operating Officer | Jun 26, 2026 | Sale | −14,748 | $38.18 | $563.08K | 227,359 |
| Jay S. Stout Chief Technology Officer | Jun 26, 2026 | Sale | −33,277 | $38.18 | $1.27M | 218,408 |
| Jay S. Stout Chief Technology Officer | Jun 26, 2026 | Sale | −6,723 | $38.94 | $261.79K | 211,685 |
| Atul Pande Director | Jun 26, 2026 | Sale(10b5-1 plan) | −1,500 | $38.01 | $57.02K | 116,731 |
| Atul Pande Director | Jun 26, 2026 | Option exercise | +1,500 | $8.43 | $12.65K | 118,231 |
| Tuyl Christopher Van Chief Legal Officer | Jun 26, 2026 | Option exercise | +17,824 | $15.20 | $270.92K | 198,421 |
| Tuyl Christopher Van Chief Legal Officer | Jun 26, 2026 | Sale | −14,982 | $38.19 | $572.16K | 183,439 |
| Tuyl Christopher Van Chief Legal Officer | Jun 26, 2026 | Sale | −2,842 | $38.96 | $110.72K | 180,597 |
| Tiago Girao Chief Financial Officer | Jun 26, 2026 | Option exercise | +10,000 | $15.90 | $159.00K | 257,596 |
| Tiago Girao Chief Financial Officer | Jun 26, 2026 | Sale | −10,000 | $38.46 | $384.60K | 247,596 |
| Tuyl Christopher Van Chief Legal Officer | Jun 18, 2026 | Sale | −2,634 | $35.39 | $93.22K | 180,597 |
| Atul Pande Director | Jun 15, 2026 | Option exercise | +1,500 | $8.43 | $12.65K | 118,231 |
| Atul Pande Director | Jun 15, 2026 | Sale(10b5-1 plan) | −1,500 | $34.02 | $51.03K | 116,731 |
| Andrew J. Fromkin Director | May 28, 2026 | Option exercise | +31,668 | $4.99 | $158.02K | 131,400 |
| Andrew J. Fromkin Director | May 28, 2026 | Option exercise | +71,492 | $7.94 | $567.65K | 202,892 |
| Andrew J. Fromkin Director | May 28, 2026 | Option exercise | +16,260 | $14.70 | $239.02K | 296,333 |
| Andrew J. Fromkin Director | May 28, 2026 | Sale | −11,483 | $32.64 | $374.81K | 284,850 |
| Andrew J. Fromkin Director | May 28, 2026 | Sale | −210,468 | $33.56 | $7.06M | 74,382 |
| Andrew J. Fromkin Director | May 28, 2026 | Option exercise | +77,181 | $8.43 | $650.64K | 280,073 |
| Melanie Gloria Chief Operating Officer | May 20, 2026 | Sale | −1,168 | $32.15 | $37.55K | 243,805 |
| Melanie Gloria Chief Operating Officer | May 20, 2026 | Sale | −1,698 | $32.95 | $55.95K | 242,107 |
| Melanie Gloria Chief Operating Officer | May 20, 2026 | Sale | −249 | $30.41 | $7.57K | 244,973 |
| Atul Pande Director | May 20, 2026 | Sale(10b5-1 plan) | −6,000 | $32.00 | $192.00K | 116,731 |
| Atul Pande Director | May 20, 2026 | Option exercise | +6,000 | $8.43 | $50.58K | 122,731 |
| Robert Graham Susman Director | May 1, 2026 | Sale(10b5-1 plan) | −2,502 | $27.17 | $67.98K | 36,394 |
| Jay S. Stout Chief Technology Officer | Apr 23, 2026 | Sale | −2,754 | $29.62 | $81.57K | 251,685 |
| Tiago Girao Chief Financial Officer | Apr 23, 2026 | Sale | −25,760 | $29.62 | $763.01K | 247,596 |
| Tuyl Christopher Van Chief Legal Officer | Apr 8, 2026 | Sale | −5,165 | $24.83 | $128.25K | 183,231 |
| Jay S. Stout Chief Technology Officer | Apr 8, 2026 | Sale | −1,518 | $24.83 | $37.69K | 254,439 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Immunovant's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,669 shares on Sep 4, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jay S. Stout Officer | Jun 26, 2026 | 40,000 | $1.53M | Jun 26, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Chris Adair Van Tuyl Officer, Director | Jun 26, 2026 | 17,824 | $682.80K | Jun 26, 2026 | Exercise of Options Under a Registered Plan |
| Melanie Gloria Officer | Jun 26, 2026 | 17,714 | $678.55K | Jun 26, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Tiago Girao Officer | Jun 26, 2026 | 10,000 | $384.64K | Jun 26, 2026 | Exercise of Options Under a Registered Plan |
| Atul Pande Director | Jun 15, 2026 | 6,000 | $201.72K | Jun 15, 2026 | Exercise of Stock Options |
| Andrew J. Fromkin Director | May 28, 2026 | 221,951 | $7.44M | May 28, 2026 | Exercise of options under a registered plan |
| Atul Pande Director | May 20, 2026 | 6,000 | $157.74K | May 20, 2026 | Exercise of Stock Options |
| Robert Graham Susman Director | May 1, 2026 | 2,502 | $67.92K | May 1, 2026 | Restricted Stock Units |
| Michael Geffner Officer | Feb 10, 2026 | 5,800 | $155.24K | Feb 10, 2026 | Restricted Stock |
| Andrew J. Fromkin Director | Dec 1, 2025 | 22,249 | $537.31K | Dec 1, 2025 | Restricted Stock Units |
| Douglas J. Hughes Director | Dec 1, 2025 | 15,000 | $362.25K | Dec 1, 2025 | Restricted Stock Units |
| Michael Geffner Officer | Nov 26, 2025 | 50,000 | $1.19M | Nov 26, 2025 | Stock Option Exercise |
| Michael Geffner Officer | Nov 25, 2025 | 103,897 | $2.43M | Nov 25, 2025 | Stock Option Exercise |
| William L. Macias Officer | Jun 25, 2025 | 30,000 | $474.86K | Jun 25, 2025 | Restricted Stock |
| William L. Macias Officer | Jun 13, 2025 | 50,000 | $778.49K | Jun 13, 2025 | Restricted Stock |
See a number that looks wrong?